Saturday, October 1, 2022


Biotechnology News Magazine

HepaTx Announces the Issuance of US Patent entitled “Methods and Composition for Producing Hepatocyte-Like Cells”

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

HepaTx reports the US Patent Office (USPTO) has granted HepaTx patent number 11291691 covering the company’s technology to manufacture hepatocyte-like cells to treat liver disease.

The patent titled “Methods and Composition for Producing Hepatocyte-Like Cells” covers critical composition of matter claims for hepatocyte-like cells manufactured from adipose-derived stromal cells.

The company’s approach to develop an off-the-shelf cell therapy to treat patients with serious liver disease is unique in that HepaTx does not genetically modify their cells, it uses adipose tissue as a starting material and is scalable to meet expected future demand. Unlike other liver therapy companies, HepaTx’s novel technology does not rely on cadaver liver tissue donations.

HepaTx is a biotechnology company focused on innovative off-the-shelf cell therapies to treat late-stage liver disease. The company also recently announced the issuance of a composition of matter patent in Japan. The US patent not only provides protection for HepaTx’s technology, but it further strengthens the company’s extensive patent portfolio.

“This patent protects HepaTx’s unique approach to manufacturing Hepatocyte-like cells and builds on our recent patents issued in Japan and other regions. These patents reflect our ability to execute on the pillars of our corporate strategy, one of which is to create additional value by strengthening and expanding our IP estate,” said Salah Kivlighn, PhD. CEO of HepaTx.

HepaTx is a cell therapy and regenerative medicine company developing new types of stem cell-based treatments for patients with late-stage liver disease, a highly underserved and cost intensive market. HepaTx’s proprietary process, licensed from Stanford and well protected by licensed IP, differentiates adipose stromal cells into functional hepatocyte-like cells.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine